Co-prescribing naloxone does not increase liability risk.
Co-prescribing naloxone does not increase liability risk.
复制标题
共同处方纳洛酮不会增加责任风险。
DOI：
10.1080/08897077.2016.1238431
复制
发表时间：
2016
期刊：
影响因子：
3.5
通讯作者：
BinswangerMdMphMs,Ingrid
中科院分区：
文献类型：
--
作者：
Davis,CoreyS;Burris,Scott;Beletsky,Leo;BinswangerMdMphMs,Ingrid
阿片类药物过量流行每年夺走数万美国人的生命。阿片类药物过量是可以通过服用纳洛酮来逆转的，纳洛酮是一种纯拮抗剂，现在可以在专门为外行人设计和标签的制剂中获得。尽管专业组织、卫生官员和临床专家广泛支持非专业人员使用纳洛酮，但定性研究表明，一些提供者担心与纳洛酮处方相关的法律风险，特别是联合给疼痛患者开纳洛酮。这种担忧是没有根据的。与开纳洛酮相关的法律风险并不高于任何其他药物，但低于许多药物。此外，大多数州的法律为开出或配发纳洛酮的提供者提供了明确的法律保护，在许多情况下，这种保护扩大到向朋友、家人和其他人开出的处方。在这个数量庞大且数量不断增加的州，善意地向有过量用药风险的患者(或在允许这样开处方的州，向此类患者的同伙)开出或分配纳洛酮的责任风险要么极低，要么完全不存在。如果处方医生在他或她的临床判断中确定患者有服药过量的风险，则联合开出纳洛酮是合理和谨慎的临床和法律决定。任何临床医生都不应基于责任方面的考虑而未能或拒绝开出这样的处方。
The opioid overdose epidemic claims the lives of tens of thousands of Americans every year. Opioid overdose is reversible by the administration of naloxone, a pure antagonist now available in formulations specifically designed and labeled for layperson use. Despite broad support for layperson access to naloxone from professional organizations, health officials, and clinical experts, qualitative studies suggest that some providers have concerns about legal risks associated with naloxone prescribing, particularly co-prescribing naloxone to pain patients. Such concerns are unfounded. The legal risk associated with prescribing naloxone is no higher than that associated with any other medication and is lower than many. Additionally, laws in a majority of states provide explicit legal protections for providers who prescribe or dispense naloxone, in many cases extending this protection to prescriptions issued to friends, family members, and others. In this large and increasing number of states, the liability risk of prescribing or dispensing naloxone in good faith to a patient at risk of overdose (or, in states where such prescribing is permitted, to an associate of such a patient) is either extremely low or absent entirely. Where a prescriber determines, in his or her clinical judgment, that a patient is at risk of overdose, co-prescribing naloxone is a reasonable and prudent clinical and legal decision. No clinician should fail or refuse to issue such a prescription based on liability concerns.